Bioventus (BVS) Revenue & Revenue Breakdown
Bioventus Revenue Highlights
Latest Revenue (Y)
$512.35M
Latest Revenue (Q)
$151.22M
Main Segment (Y)
Pain Treatments
Main Geography (Y)
UNITED STATES
Bioventus Revenue by Period
Bioventus Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $512.35M | 0.04% |
| 2022-12-31 | $512.12M | 18.85% |
| 2021-12-31 | $430.90M | 34.17% |
| 2020-12-31 | $321.16M | -5.58% |
| 2019-12-31 | $340.14M | 6.57% |
| 2018-12-31 | $319.18M | 25.83% |
| 2015-12-31 | $253.65M | 4.43% |
| 2014-12-31 | $242.89M | 4.53% |
| 2013-12-31 | $232.38M | 258.75% |
| 2000-01-01 | $64.77M | - |
Bioventus generated $512.35M in revenue during NA 2023, up 0.04% compared to the previous quarter, and up 160.52% compared to the same period a year ago.
Bioventus Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-29 | $151.22M | 16.81% |
| 2024-03-30 | $129.46M | -4.41% |
| 2023-12-31 | $135.42M | 12.11% |
| 2023-09-30 | $120.79M | -11.87% |
| 2023-07-01 | $137.07M | 15.13% |
| 2023-04-01 | $119.06M | -5.38% |
| 2022-12-31 | $125.83M | -8.20% |
| 2022-10-01 | $137.07M | -2.32% |
| 2022-07-02 | $140.33M | 19.64% |
| 2022-04-02 | $117.29M | -10.06% |
| 2021-12-31 | $130.41M | 19.77% |
| 2021-10-02 | $108.89M | -0.84% |
| 2021-07-03 | $109.82M | 34.29% |
| 2021-04-03 | $81.78M | -17.05% |
| 2020-12-31 | $98.59M | 14.76% |
| 2020-09-30 | $85.91M | 48.07% |
| 2020-06-30 | $58.02M | -26.23% |
| 2020-03-31 | $78.64M | -19.38% |
| 2019-12-31 | $97.55M | 49.16% |
| 2016-03-31 | $65.40M | 22.56% |
| 2015-03-31 | $53.36M | - |
Bioventus generated $151.22M in revenue during Q2 2024, up 16.81% compared to the previous quarter, and up 127.01% compared to the same period a year ago.
Bioventus Revenue Breakdown
Bioventus Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 |
|---|---|
| Surgical Solutions | $87.72M |
| Pain Treatments | $221.61M |
| Restorative Therapies | $121.57M |
Bioventus's latest annual revenue breakdown by segment (product or service), as of Dec 21: Pain Treatments (51.43%), Restorative Therapies (28.21%), and Surgical Solutions (20.36%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Jul 22 | Apr 22 | Dec 21 | Oct 21 | Jul 21 | Apr 21 |
|---|---|---|---|---|---|---|---|---|
| International Segment | $16.81M | $15.18M | - | - | - | - | - | - |
| U.S. Segment | $134.41M | $114.28M | - | - | - | - | - | - |
| Surgical Solutions | - | - | $36.52M | $30.88M | - | - | - | - |
| Restorative Therapies | - | - | $39.90M | $34.36M | $36.77M | $30.48M | $32.51M | $21.82M |
| Pain Treatments | - | - | $63.91M | $52.05M | - | - | - | - |
| Pain Treatments And Joint Preservation | - | - | - | - | - | $60.63M | $56.70M | $41.53M |
| Bone Graft Substitutes | - | - | - | - | - | $17.78M | $20.60M | $18.43M |
Bioventus's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: U.S. Segment (88.88%), and International Segment (11.12%).
Bioventus Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Non-US | $62.48M | $14.95M | $43.34M |
| UNITED STATES | $449.86M | $126.21M | $387.55M |
Bioventus's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (87.80%), and Non-US (12.20%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Jul 23 | Dec 22 | Oct 22 | Jul 22 | Apr 22 | Dec 21 | Oct 21 | Jul 21 | Apr 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $16.81M | $15.18M | $26.90M | $5.42M | $4.41M | $3.24M | $14.02M | $13.21M | $15.24M | $9.73M | $11.13M | $7.24M |
| UNITED STATES | $134.41M | $114.28M | $208.52M | $33.39M | $34.94M | $31.18M | $126.31M | $104.08M | $115.17M | $99.16M | $98.68M | $74.54M |
Bioventus's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (88.88%), and Non-US (11.12%).
Bioventus Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BVS | Bioventus | $512.35M | $151.22M |
| RPID | Rapid Micro Biosystems | $22.52M | $6.62M |
| HSCS | Heart Test Laboratories | $18.60M | $14.70K |
| VVOS | Vivos Therapeutics | $13.80M | $4.05M |
| NUWE | Nuwellis | $8.86M | $2.19M |
| NAOV | NanoVibronix | $2.28M | $817.00K |
| TIVC | Tivic Health Systems | $1.18M | $140.00K |
| TLIS | Talis Biomedical | $412.00K | - |
| BJDX | Bluejay Diagnostics | - | - |
| BBLG | Bone Biologics | - | - |
BVS Revenue FAQ
What is Bioventus’s yearly revenue?
Bioventus's yearly revenue for 2023 was $512.34M, representing an increase of 0.04% compared to 2022. The company's yearly revenue for 2022 was $512.12M, representing an increase of 18.85% compared to 2021. BVS's yearly revenue for 2021 was $430.9M, representing an increase of 34.17% compared to 2020.
What is Bioventus’s quarterly revenue?
Bioventus's quarterly revenue for Q2 2024 was $151.22M, a 16.81% increase from the previous quarter (Q1 2024), and a 10.32% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $129.46M, a -4.41% decrease from the previous quarter (Q4 2023), and a 8.73% increase year-over-year (Q1 2023). BVS's quarterly revenue for Q4 2023 was $135.42M, a 12.11% increase from the previous quarter (Q3 2023), and a 7.62% increase year-over-year (Q4 2022).
What is Bioventus’s revenue growth rate?
Bioventus's revenue growth rate for the last 3 years (2021-2023) was 18.90%, and for the last 5 years (2019-2023) was 50.63%.
What are Bioventus’s revenue streams?
Bioventus's revenue streams in c 21 are Surgical Solutions, Pain Treatments, and Restorative Therapies. Surgical Solutions generated $87.72M in revenue, accounting 20.36% of the company's total revenue Pain Treatments generated $221.61M in revenue, accounting 51.43% of the company's total revenue Restorative Therapies generated $121.57M in revenue, accounting 28.21% of the company's total revenue
What is Bioventus’s main source of revenue?
For the fiscal year ending Dec 21, the largest source of revenue of Bioventus was Pain Treatments. This segment made a revenue of $221.61M, representing 51.43% of the company's total revenue.